Tafenoquine in Patients With Mild to Moderate COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

February 19, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
COVID 19 Disease
Interventions
DRUG

Tafenoquine Oral Tablet

Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.

DRUG

Placebo

Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.

Trial Locations (10)

28655

Burke Primary Care, Morgantown

29640

AFC Urgent Care, Easley

33014

Deluxe Health Center LLC, Miami

33165

Hope Clinical Trials, Miami

33184

F&T Medical Research, Inc., Miami

33185

Kendall South Medical Center, Inc., Miami

68022

Skyline Medical Center, Elkhorn

75126

Care United, Forney

77074

Clinical Trial Network, Houston

78526

Centex Studies, Brownsville

Sponsors
All Listed Sponsors
lead

60 Degrees Pharmaceuticals LLC

INDUSTRY

NCT04533347 - Tafenoquine in Patients With Mild to Moderate COVID-19 | Biotech Hunter | Biotech Hunter